• A 'startup' Genentech, but focused on developing novel cancer therapies.
• A specialized biotech, similar to how Vertex Pharmaceuticals started, but focused on targeted cancer treatments.

• APRE-246 (eprenetapopt): A small molecule drug candidate designed to reactivate mutant p53 tumor suppressor protein, primarily investigated for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
• APR-548: A next-generation, orally administered small molecule drug candidate engineered to reactivate mutant p53 protein for various oncology indications.

Aprea Therapeutics (symbol: APRE) was a clinical-stage biopharmaceutical company focused on developing therapies for cancer, particularly myeloid neoplasms. Its lead product candidate, eprenetapopt (APR-246), was undergoing clinical trials but did not receive regulatory approval for commercialization.

As a clinical-stage company without any approved or commercialized products generating sales revenue, Aprea Therapeutics did not have "major customers" in the traditional sense of companies or individuals purchasing its products.

The company's financial activities and "revenue" streams primarily consisted of funding through research and development collaborations, grants, and equity financing, rather than sales to customers for its therapeutic candidates.

• WuXi AppTec (2359.HK, 603259.SS)

Oren Gilad, Ph.D. President and Chief Executive Officer

Oren Gilad, Ph.D., has served as Chief Executive Officer of Aprea Therapeutics since July 2022 and as President and a member of its Board of Directors since May 2022. He previously served as President and CEO of Atrin Pharmaceuticals, Inc., which he founded in 2011. Dr. Gilad led Atrin Pharmaceuticals from its initial concept through the successful development of its pipeline of anti-cancer therapies, ultimately leading to its acquisition by Aprea Therapeutics in May 2022. He brings extensive experience across multiple phases of drug development, including securing financing to support preclinical and clinical development, regulatory, and intellectual property activities during his time at Atrin.

John P. Hamill, CPA Senior Vice President and Chief Financial Officer

John P. Hamill, CPA, joined Aprea Therapeutics in January 2023. He previously served as Senior Vice President and Chief Financial Officer at Windtree Therapeutics since 2020. Mr. Hamill brings over 30 years of financial leadership experience in the pharmaceutical, biopharmaceutical, and clinical research sectors. His experience includes financial, administrative, information technology, and facility functions, and he has successfully completed initial public offerings (IPOs) and follow-on offerings for several pharmaceutical companies.

Ze'ev Weiss, CPA, B.S. Chief Business Advisor

Ze'ev Weiss has served as Chief Business Advisor for Aprea Therapeutics since May 2022. He brings over 20 years of broad and extensive biopharmaceutical industry experience in strategic, operational, and corporate development. Mr. Weiss previously served as Chief Business Officer of Atrin Pharmaceuticals Inc. at the time of its acquisition by Aprea, and prior to that, he was the CEO of a clinical-stage biopharmaceutical company, leading it through its IPO on NASDAQ.

Brian Wiley Senior Vice President of Corporate Development & Strategy

Brian Wiley joined Aprea Therapeutics as Senior Vice President of Corporate Development & Strategy in November 2023. He has over 30 years of experience in the biopharmaceutical industry, with more than 25 years dedicated to oncology. His experience as a senior business development executive includes numerous licensing transactions, collaborations, mergers and acquisitions (M&A), and public and private financings, having been a major contributor to transactions exceeding $5 billion and financing in excess of $150 million.

Mike Carleton, Ph.D. Translational Medicine Advisor

Mike Carleton, Ph.D., has served as Translational Medicine Advisor for Aprea Therapeutics since May 2022. He brings over 20 years of experience in the pharmaceutical/biotech industry, holding leadership roles in preclinical and clinical drug development. Dr. Carleton most recently served as Vice President of Translational Medicine at Inipharm and was Vice President of Translational Medicine at Mavupharma until Abbvie's acquisition of Mavu and its ENPP1 inhibitor program.

The key risks to Aprea Therapeutics' (symbol: APRE) business are primarily related to its financial viability, the inherent challenges of drug development and regulatory approval, and competitive market pressures.

1. Financing Dependence and Going Concern: Aprea Therapeutics faces a significant risk due to its limited cash runway and dependence on future financing. The company has explicitly disclosed "substantial doubt about its ability to continue as a going concern" and expects its current cash to fund operations only into the first quarter of 2026. The need for additional capital raises, which may involve equity, debt, or collaborations, is anticipated and will likely dilute existing shareholders.
2. Regulatory Challenges and Clinical Trial Success: As a clinical-stage biopharmaceutical company, Aprea Therapeutics' success hinges on the rigorous regulatory review and potential approval of its product candidates, with no guarantee of such approval. The success, timing, and cost of its ongoing and anticipated clinical trials for candidates like APR-1051 and ATRN-119 are critical, and there is inherent uncertainty regarding trial enrollment, preliminary results, and the ability to predict clinical outcomes. Historically, the company has experienced FDA holds on programs due to safety concerns, underscoring the regulatory hurdles and potential for delays.
3. Market Dependence and Competition: Aprea's future success relies heavily on the commercial viability of its lead product candidates. The oncology space, where Aprea operates, is characterized by intense competition from other pharmaceutical and biotechnology firms, which could impact the company's market share and profitability if its therapies are approved.

null

Aprea Therapeutics (APRE) is a clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics, with its future revenue growth over the next 2-3 years primarily driven by the advancement and potential commercialization of its lead pipeline candidates. The company's strategic focus on precision oncology through synthetic lethality underpins these drivers.

Here are 4 expected drivers of future revenue growth for Aprea Therapeutics:

• Successful Clinical Development and Potential Commercialization of APR-1051 (WEE1 Inhibitor): APR-1051 is Aprea's next-generation WEE1 kinase inhibitor, currently in Phase 1 clinical evaluation for advanced solid tumors. The company anticipates reporting preliminary efficacy data in the second half of 2025, with the completion of the dose-escalation phase expected in the first half of 2026. Positive clinical outcomes and progression towards regulatory approval for this candidate would be a significant revenue driver.
• Successful Clinical Development and Potential Commercialization of ATRN-119 (ATR Inhibitor): ATRN-119 is a novel macrocyclic ATR inhibitor, also in Phase 1 development, designed to target the DNA damage response pathway in solid tumor indications. Early evidence of single-agent anti-tumor activity has been observed, and the recommended Phase 2 dose is expected to be identified in the first half of 2026. The successful advancement and eventual commercialization of ATRN-119 are crucial for future revenue generation.
• Expansion of APR-1051 into New Indications and Combination Therapies: Aprea is actively advancing APR-1051 as a monotherapy for cancers with Cyclin E over-expression and other specific biomarkers that may predict sensitivity to WEE1 inhibition. Furthermore, future arms of the ACESOT-1051 study may explore APR-1051 in combination with checkpoint inhibitors, which could broaden its market potential and create additional revenue streams by addressing a wider range of patient populations and tumor types.
• Expansion of ATRN-119 into New Indications and Combination Therapies: The potential for ATRN-119 to be an ideal DNA Damage Response (DDR) inhibitor for novel combination therapies is a key aspect of its development. Pending additional data, future arms of the ABOYA-119 trial may evaluate ATRN-119 in combination with other treatments. Expanding the therapeutic utility of ATRN-119 through new indications and combination strategies would enhance its market opportunity and contribute to revenue growth.

Share Issuance

• In February 2023, Aprea Therapeutics priced an underwritten public offering of 1,050,000 shares of its common stock at $5.25 per share, resulting in gross proceeds of approximately $5.5 million.
• The net proceeds from this offering were intended to fund the continued development of its clinical asset ATRN-119, preclinical asset ATRN-W1051, and for general corporate purposes.

Inbound Investments

• Aprea Therapeutics' latest funding round was a Post IPO round on March 11, 2024, involving investors such as Rock Springs Capital, Versant Ventures, 5AM Ventures, Janus Henderson Investors, Nantahala Capital Management, DAFNA Capital Management, Exome Asset Management, Sphera Fund, and Stonepine.

Outbound Investments

• In May 2022, Aprea Therapeutics acquired Atrin Pharmaceuticals Inc., subsequently shifting the focus of its activities to the assets acquired from Atrin.

Capital Expenditures

• As of March 31, 2025, Aprea Therapeutics projected that its cash and cash equivalents would be sufficient to meet its operating expenses and capital expenditure requirements into early Q2 2026.
• As of June 30, 2025, the company estimated its cash and cash equivalents of $16.5 million would be sufficient to meet its projected operating expenses and capital expenditure requirements into Q2 2026.